State Attorney General Is Investigating Lilly and AstraZeneca’s 340B Pricing

Eli Lilly and AstraZeneca are the latest drug makers to disclose that they have been subpoenaed by Vermont's top law enforcement official for documents and information about their participation in 340B. | Shutterstock

Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.

Lilly and

Read More »

Hospital Groups Want FDA to Curtail Specialty Drug White Bagging

Hospital groups are growing more concerned about white bagging—the payer practice of requiring them to obtain specialty drugs, often for cancer treatment, from the payer's chosen specialty pharmacies. | Shutterstock

The American Hospital Association (AHA) and ASHP (the American Society of Health-System Pharmacists) want the U.S. Food and Drug Administration (FDA) to “take appropriate action” against white bagging—the health care payer requirement that hospitals obtain specialty drugs for insured patients

Read More »

Study: Patients with Deductibles and Coinsurance Pay More When a Drug’s List Price Rises

A new study in JAMA Open Network found that, when brand drug manufacturers raise their list prices, commercially insured patients with deductibles and coinsurance do not directly benefit from the secret rebates the manufacturers pay insurance companies and PBMs. | Shutterstock

Commercially insured patients with deductibles and coinsurance pay more when manufacturers raise a drug’s list price and do not directly benefit from the confidential rebates paid by manufacturers to insurers, according to a study published this morning in JAMA Open

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live